JPRN-UMIN000001246已完成2 期
Randomized phase II trial comparing amrubicine/irinotecan with cisplatin/irinotecan in patients with extensive-stage small-cell lung cancer: (JMTO LC 08-01) - Randomized phase II trial comparing amrubicine/irinotecan with cisplatin/irinotecan in patients with ED-SCLC: (JMTO LC 08-01)
The Japan-multinational Trial Organization0 个研究点目标入组 100 人开始时间: 2008年7月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)uncontrollable pleural, pericardial effusion or ascites 2)uncontrolled heart disease 3)uncontrolled diabetes mellitus 4)active infection 5)radiotherapy including pulmonary field 6)interstitial pneumonia/active lung fibrosis on chest x-ray 7)patients who has been taking steroid or immunosuppressant for any other disease 8)watery diarrhea, intestinal paralysis or obstruction 9)history of severe drug allergy 10)active concomitant malignancy 11)pregnant or lactating woman 12)patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
进行中（未招募）
不适用
Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC ES - NDPatient with small cell lung cancer.MedDRA version: 6.1Level: PTClassification code 10041068EUCTR2006-001956-11-ITCABRELLIS PHARMACEUTICALS CORPORATIO85
尚未招募
2 期
Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC (ES).lung cancerNL-OMON30640European Organisation for Research in Treatment of Cancer (EORTC)14
进行中（未招募）
不适用
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCSmall Cell Lung Cancer (extensive stage)MedDRA version: 8.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2006-001956-11-NLCabrellis Pharmaceuticals Corporation85
进行中（未招募）
不适用
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCSmall Cell Lung Cancer (extensive stage)MedDRA version: 8.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2006-001956-11-BECelgene International SAR97
进行中（未招募）
1 期
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCEUCTR2006-001956-11-GBCelgene International SAR97